Adverse events leading to treatment discontinuation
| Patients, n (%) . | G-FC (n = 21) . | G-B (n = 20) . |
|---|---|---|
| Total number of patients with at least 1 adverse event leading to discontinuation | 7 (33) | 2 (10) |
| Overall total number of events | 9 | 2 |
| Neutropenia | 3 (15) | 2 (10) |
| Pancytopenia | 1 (5) | 0 |
| Thrombocytopenia | 2 (10) | 0 |
| ALT/AST increased | 2 (10) | 0 |
| Cellulitis | 1 (5) | 0 |
| Patients, n (%) . | G-FC (n = 21) . | G-B (n = 20) . |
|---|---|---|
| Total number of patients with at least 1 adverse event leading to discontinuation | 7 (33) | 2 (10) |
| Overall total number of events | 9 | 2 |
| Neutropenia | 3 (15) | 2 (10) |
| Pancytopenia | 1 (5) | 0 |
| Thrombocytopenia | 2 (10) | 0 |
| ALT/AST increased | 2 (10) | 0 |
| Cellulitis | 1 (5) | 0 |
ALT, alanine aminotransferase; AST, aspartate aminotransferase.